Eczema & Dermatitis
Comprehensive integrative medicine approach for lasting healing and complete recovery
Understanding Eczema & Dermatitis
Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that causes intense itching, dry skin, and recurring red rashes. It results from a defective skin barrier that allows moisture to escape and irritants to enter, combined with an overactive immune system response. This condition often begins in early childhood and can persist into adulthood, frequently occurring alongside asthma and allergic rhinitis (the 'atopic triad').
Recognizing Eczema & Dermatitis
Common symptoms and warning signs to look for
Intense itching (pruritus) - especially at night, often before the rash appears
Dry, scaly skin - rough texture that cracks and peels
Red, inflamed patches - typically on flexural surfaces (elbows, knees, neck, wrists)
Thickened, leathery skin - from chronic scratching (lichenification)
Small bumps that ooze and crust - when scratched, leading to infection risk
What a Healthy System Looks Like
In a healthy individual, the skin barrier functions as the body's primary defense system: The stratum corneum (outermost layer) maintains optimal hydration through properly organized corneocytes and intercellular lipids that prevent transepidermal water loss (TEWL). The epidermal tight junctions prevent allergen and pathogen penetration. The skin microbiome maintains a diverse community of beneficial bacteria (Staphylococcus epidermidis, Cutibacterium acnes) that outcompete pathogenic organisms. Resident immune cells (Langerhans cells, dermal dendrocytes) mount appropriate defensive responses without triggering excessive inflammation. The skin's natural moisturizing factor (NMF) - derived from filaggrin protein breakdown - maintains optimal skin pH (5.5) and hydration levels. Keratinocyte turnover is balanced at approximately 28 days, and the skin heals rapidly without scarring when damaged.
How the Condition Develops
Understanding the biological mechanisms
Atopic dermatitis involves multi-system dysfunction at the cellular level: (1) Filaggrin Deficiency - FLG gene mutations (R501X, 2282del4) reduce filaggrin production, leading to impaired barrier function, increased TEWL, and decreased NMF by 50-80%; (2) Stratum Corneum Dysfunction - Abnormal lipid composition with reduced ceramides (1, 3, 6-II), cholesterol, and free fatty acids compromises the 'mortar and brick' structure; (3) Th2-Mediated Inflammation - Allergen exposure triggers IL-4, IL-5, IL-13, and IL-31 release from Th2 cells, driving eosinophilic infiltration and intense pruritus; (4) IgE Elevation - Class-switching to IgE antibodies creates sensitization to environmental allergens, with mast cell and basophil degranulation releasing histamine, tryptase, and cytokines; (5) Tight Junction Dysfunction - Claudin-1 deficiency allows paracellular allergen passage through the epidermis; (6) Microbiome Imbalance - Reduced microbial diversity with Staphylococcus aureus colonization (present in 80% of AD patients) triggers inflammation through superantigens and exotoxins; (7) Itch-Scratch Cycle - IL-31 (the 'itch cytokine') activates sensory nerve fibers (TRPV1, PAR-2), triggering scratch that further damages the barrier; (8) Neuroimmune Dysregulation - Increased nerve density in lesional skin and altered neuropeptide release (substance P, CGRP) amplify itch perception and neurogenic inflammation.
Key Laboratory Markers
Important values for diagnosis and monitoring
| Test | Normal Range | Optimal | Significance |
|---|---|---|---|
| Total Serum IgE | <100 IU/mL | <30 IU/mL | Elevated in 80% of AD patients; correlates with disease severity and atopic comorbidities; values >1000 IU/mL suggest severe atopy and possible hyper-IgE syndrome |
| Blood Eosinophils | <500 cells/mcL | <150 cells/mcL | Eosinophilia common in AD; elevated counts indicate Th2-driven inflammation and predict disease severity; counts >1000 suggest eosinophilic dermatitis |
| IL-4 (Interleukin-4) | <10 pg/mL | <5 pg/mL | Key Th2 cytokine elevated in AD; drives IgE class-switching and eosinophil recruitment; therapeutic target of dupilumab |
| IL-13 (Interleukin-13) | <10 pg/mL | <5 pg/mL | Central cytokine in AD pathogenesis; promotes pruritus, barrier dysfunction, and Th2 inflammation; therapeutic target of dupilumab |
| IL-31 (Interleukin-31) | <50 pg/mL | <20 pg/mL | Primary itch cytokine; elevated levels correlate with pruritus severity and disease activity; direct activator of itch sensory nerves |
| 25-Hydroxy Vitamin D | 30-100 ng/mL | 50-80 ng/mL | Vitamin D modulates immune function and skin barrier; deficiency associated with increased AD severity and infection risk |
| Serum Zinc | 60-120 mcg/dL | 80-120 mcg/dL | Zinc essential for wound healing, immune function, and barrier repair; deficiency impairs keratinocyte proliferation and healing |
| Transepidermal Water Loss (TEWL) | <10 g/m²/h | <8 g/m²/h | Direct measure of barrier function; elevated TEWL (>15 g/m²/h) indicates compromised stratum corneum and active disease |
| TARC (Thymus and Activation-Regulated Chemokine) | <450 pg/mL | <200 pg/mL | Th2 chemoattractant; elevated in active AD; useful marker for disease activity and treatment response |
Root Causes We Address
The underlying factors contributing to your condition
{"cause":"Genetic Filaggrin Deficiency","contribution":"30-50% of moderate-severe AD cases - FLG gene mutations (R501X, 2282del4, S3297X) cause filaggrin deficiency leading to impaired barrier function, increased TEWL by 30-50%, and reduced NMF by 50-80%; inherited in autosomal dominant pattern with incomplete penetrance; predicts early-onset, severe disease and atopic march progression","assessment":"Genetic testing for FLG mutations via commercial panels; detailed family history of atopy; early-onset severe AD in infancy suggests genetic etiology; also test for other barrier-related genes (FLG2, SPINK5, TMEM79)"}
{"cause":"Skin Barrier Dysfunction","contribution":"Universal feature of AD - Abnormal epidermal lipid composition with 30-50% reduction in ceramides (especially ceramide 1, 3, 6-II), impaired corneocyte desquamation due to kallikrein dysregulation, and tight junction defects (claudin-1 deficiency) allowing allergen penetration and water loss","assessment":"TEWL measurement via Tewameter; skin pH testing (elevated >6.0); capacitance hydration measurement; lipid panel analysis from skin biopsies; clinical assessment using SCORAD"}
{"cause":"Immune Dysregulation (Th2 Dominance)","contribution":"Core pathological mechanism - IL-4, IL-5, IL-13, IL-31 drive eosinophilic inflammation, IgE class-switching, and pruritus; impaired Th1 response reduces antimicrobial defense; Th22 cells produce IL-22 contributing to epidermal hyperplasia","assessment":"Serum total IgE levels; blood eosinophil count; cytokine panels (IL-4, IL-13, IL-31, IL-22); specific IgE testing to common allergens; patch testing"}
{"cause":"Environmental Allergens","contribution":"60-80% of cases triggered or exacerbated - Dust mites (Dermatophagoides pteronyssinus, D. farinae) are most common, followed by pollen (tree, grass, weed), pet dander, mold spores (Aspergillus, Penicillium), and cockroach allergens; penetrate defective barrier and trigger IgE-mediated inflammation","assessment":"Skin prick testing with standard panels; serum specific IgE panel (ImmunoCAP); environmental home assessment for allergen burden; bedroom allergen encasement evaluation"}
{"cause":"Microbiome Imbalance (Dysbiosis)","contribution":"80% of AD patients have S. aureus colonization (vs. 5-30% of healthy controls) - Superantigens (toxic shock syndrome toxin-1, staphylococcal enterotoxins SEA, SEB) trigger massive T-cell activation and inflammation; reduced microbial diversity loses competitive inhibition; reduced antimicrobial peptides (LL-37, beta-defensin)","assessment":"Skin swab cultures from lesional and non-lesional skin; microbiome sequencing (16S rRNA); clinical assessment for infected eczema lesions; staph carriage screening"}
{"cause":"Nutritional Deficiencies","contribution":"30-40% of patients have contributing deficiencies - Vitamin D deficiency impairs immune regulation and barrier repair; zinc deficiency delays wound healing and increases infection risk; omega-3 deficiency reduces anti-inflammatory mediators (resolvins, protectins); iron deficiency worsens pruritus","assessment":"Serum 25-OH vitamin D; serum zinc; omega-3 index (RBC fatty acid analysis); ferritin and iron studies; comprehensive metabolic panel"}
{"cause":"Psychological Stress and Emotional Factors","contribution":"Significant contributor in 40-60% of flares - Stress activates HPA axis and sympathetic nervous system, releasing CRH, cortisol, and neuropeptides (substance P, CGRP) that trigger itch and worsen inflammation; stress-induced scratching intensifies itch-scratch cycle; cortisol dysregulation alters immune function","assessment":"Comprehensive stress history; Perceived Stress Scale (PSS-10); validated anxiety/depression screening (PHQ-9, GAD-7); itch diary correlating with stress events"}
{"cause":"Food Sensitivities and Allergies","contribution":"30-40% of cases, especially in children - IgE-mediated immediate reactions to cow's milk, eggs, peanuts, soy, wheat, fish, shellfish; non-IgE-mediated delayed reactions also occur; food-specific T-cell responses contribute; oral tolerance failure in barrier dysfunction","assessment":"Food-specific IgE testing (ImmunoCAP); skin prick with food extracts; elimination diets (6-8 weeks); supervised oral food challenges; food sensitivity panels (IgG - controversial)"}
{"cause":"Climate and Environmental Factors","contribution":"Major environmental triggers - Low humidity (winter, air conditioning, heating) strips skin lipids; hard water (high calcium) impairs barrier; extreme temperatures (hot or cold) trigger flares; UV exposure has variable effects (some benefit, some worsen); sweating irritates skin","assessment":"Climate and seasonal history; geographic relocation patterns; water hardness testing; home environment assessment (humidity, heating, cooling)"}
{"cause":"Hormonal Factors","contribution":"Pre-menstrual flares in women (20-30%); pregnancy improves or worsens AD equally; thyroid dysfunction can mimic or exacerbate; stress hormones (cortisol, catecholamines) directly affect immune function","assessment":"Hormone panel (TSH, free T3/T4, estrogen, progesterone, cortisol); menstrual cycle correlation with flares; pregnancy history"}
Risks of Inaction
What happens if left untreated
{"complication":"Secondary Skin Infections","timeline":"Ongoing risk throughout disease course","impact":"Compromised barrier allows bacterial (Staphylococcus aureus, Streptococcus pyogenes), viral (HSV causing eczema herpeticum - potentially life-threatening), and fungal invasion; recurrent infections increase antibiotic resistance; impetigo complicates 20-30% of cases; cellulitis requires hospitalization"}
{"complication":"Sleep Deprivation and Cognitive Impairment","timeline":"Chronic, daily impact","impact":"Nocturnal pruritus causes average 2+ hours sleep loss per night; children lose 1+ hours of learning time daily; chronic sleep debt increases accident risk, impairs concentration and memory, worsens mood disorders; affects work performance by 20-40%"}
{"complication":"Psychological Morbidity","timeline":"Chronic, progressive","impact":"AD patients have 2-3x higher rates of anxiety and depression; visible lesions cause social stigma and avoidance; 30% report significant quality of life impact; children experience bullying and social exclusion; increased suicide risk in severe cases"}
{"complication":"Atopic March Progression","timeline":"Months to years, typically in childhood","impact":"50% of children with moderate-severe AD develop asthma (3-4x increased risk); 40% develop allergic rhinitis; 20% develop food allergies; early intervention with barrier repair may interrupt this progression"}
{"complication":"Permanent Skin Changes and Scarring","timeline":"Years of chronic disease","impact":"Chronic scratching causes lichenification (permanent skin thickening), dyspigmentation (hypopigmentation or hyperpigmentation lasting months to years), atrophic scarring, and permanent texture changes affecting self-esteem long-term"}
{"complication":"Workplace and Social Impairment","timeline":"Ongoing, affects adult patients","impact":"AD causes more lost workdays than any other skin condition (average 3-5 days/year); visible lesions limit career choices in customer-facing roles; social activities curtailed; relationship strain; financial burden from ongoing treatments"}
{"complication":"Treatment Burden and Healthcare Costs","timeline":"Lifetime","impact":"Average AD patient spends $2000-5000+ annually on treatments, prescriptions, and doctor visits; emergency visits for infected eczema or severe flares; indirect costs from lost productivity estimated at $1-3 billion annually in the US alone"}
{"complication":"Development of Contact Allergy","timeline":"Years of disease","impact":"Prolonged topical steroid use can cause contact allergy (5-10%); frequent use of moisturizers with fragrances or preservatives leads to sensitization; complicates treatment and requires patch testing"}
How We Diagnose
Comprehensive assessment methods we use
{"test":"Comprehensive Atopic Panel","purpose":"Confirm atopic diathesis and identify specific triggers","whatItShows":"Total IgE levels, specific IgE to common allergens (dust mites D. pteronyssinus and D. farinae, grass pollen mix, tree pollen mix, weed pollen, cat dander, dog dander, mold mix, food panel); eosinophil count; guides allergen avoidance and consideration for allergen immunotherapy"}
{"test":"Cytokine Panel (IL-4, IL-13, IL-31, IL-22)","purpose":"Assess Th2/Th22 inflammatory burden","whatItShows":"Elevated Th2 cytokines (IL-4, IL-13) confirm immune-driven pathogenesis; IL-31 levels correlate with pruritus severity; IL-22 indicates epidermal hyperplasia; useful for monitoring treatment response to biologics"}
{"test":"Skin Barrier Assessment (TEWL, pH, Hydration)","purpose":"Quantify barrier dysfunction objectively","whatItShows":"Elevated TEWL (>15 g/m²/h in active disease vs. normal <10) indicates impaired barrier; elevated pH (>6.0 vs. normal 5.5) disrupts antimicrobial function and enzyme activity; low capacitance/hydration correlates with xerosis severity"}
{"test":"Patch Testing (Contact Allergy)","purpose":"Identify allergic contact dermatitis complicating AD","whatItShows":"Identifies contact allergens including fragrances (fragrance mix I, II), preservatives (methylisothiazolinone, formaldehyde releasers), metals (nickel), topical antibiotics (neomycin, bacitracin), corticosteroids (hydrocortisone, budesonide), and excipients"}
{"test":"Microbiome Analysis (Skin Swab/Sequencing)","purpose":"Assess skin bacterial diversity and pathogen burden","whatItShows":"Reduced overall diversity; S. aureus dominance (>50% of isolates) indicates dysbiosis; guides probiotic therapy, antimicrobial strategies (bleach baths, intranasal mupirocin), and microbiome restoration protocols"}
{"test":"Nutritional Assessment Panel","purpose":"Identify deficiency-related contributors to barrier dysfunction","whatItShows":"25-OH vitamin D (deficiency <20 ng/mL common in AD); serum zinc; omega-3 index (target >8% for anti-inflammatory effect); ferritin; comprehensive metabolic panel; identifies supplementation needs"}
{"test":"Genetic Testing (Barrier Genes)","purpose":"Confirm genetic predisposition and inform prognosis","whatItShows":"FLG mutations (R501X, 2282del4, S3297X) confirm hereditary barrier defect; predicts early-onset, severe disease and atopic march risk; FLG2, SPINK5, and TMEM79 mutations also implicated; guides intensity of early intervention"}
{"test":"Food Allergy Testing","purpose":"Identify food triggers in IgE-mediated allergy","whatItShows":"Specific IgE (ImmunoCAP) to common food allergens; skin prick testing with fresh foods; distinguishes IgE-mediated (immediate) from non-IgE-mediated (delayed) reactions; oral food challenge is gold standard"}
{"test":"SCORAD Assessment","purpose":"Standardized clinical severity measurement","whatItShows":"Scoring Atopic Dermatitis index combines area affected, intensity (redness, swelling, crusting, lichenification, dryness), and subjective symptoms (pruritus, sleep loss); used to grade severity and monitor treatment response"}
Our Treatment Approach
How we help you overcome Eczema & Dermatitis
Healers Skin Barrier Restoration & Immune Modulation Protocol
Healers Skin Barrier Restoration & Immune Modulation Protocol
Diet & Lifestyle
Recommendations for optimal recovery
Recovery Timeline
What to expect on your healing journey
{"initialImprovement":"2-4 weeks - Noticeable reduction in pruritus intensity (30-50% decrease), improved sleep quality within first week, decreased redness and scaling visible by week 2, fewer scratch-induced lesions, reduced need for rescue topical steroids","significantChanges":"3-6 months - Marked improvement in skin barrier function (TEWL reduced by 30-50% toward normal), normalized skin hydration levels, decreased flare frequency (target >50% reduction), visible healing of chronic lichenified lesions, improved quality of life scores (EASI, SCORAD, DLQI), reduced systemic inflammation markers","maintenancePhase":"6-12 months - Sustained remission with minimal active lesions (SCORAD <15), stable barrier function maintained with maintenance therapy, significantly reduced treatment requirements, ability to recognize and intervene early at warning signs of flares, psychological wellbeing improved, prevention of atopic march progression in children"}
How We Measure Success
Outcomes that matter
Pruritus intensity reduced by >50% (validated itch scales: Peak Itch Numeric Rating Scale, ItchyQoL)
SCORAD (Scoring Atopic Dermatitis) index improvement >50% from baseline
EASI (Eczema Area and Severity Index) improvement >50%
Transepidermal water loss reduced to <10 g/m²/h (ideally <8)
Skin hydration restored to normal levels (>40 units on Corneometer)
Flare frequency reduced by >75% compared to pre-treatment
Sleep quality restored (minimal nocturnal scratching, >7 hours uninterrupted)
No secondary skin infections during treatment period
Reduced topical corticosteroid use (steroid-sparing achieved)
Improved quality of life (Eczema Area and Severity Index, DLQI >50% improvement)
Stable remission maintained with maintenance therapy alone
Normalization of inflammatory markers (IgE, eosinophils, cytokines)
Patient-reported satisfaction and treatment adherence
Frequently Asked Questions
Common questions from patients
What is the best treatment for eczema?
The most effective eczema treatment is personalized and combines multiple approaches: (1) Barrier repair through regular moisturization with ceramide-rich emollients applied within 3 minutes of bathing; (2) Anti-inflammatory therapy with topical corticosteroids (use appropriate potency for body part) or steroid-sparing topical calcineurin inhibitors; (3) Trigger avoidance based on your specific allergens (identified through testing); (4) For moderate-severe cases, advanced treatments like dupilumab (Dupixent), tralokinumab (Adbry), or upadacitinib (Rinvoq) target the underlying Th2 inflammation. The key is working with a provider who understands the complex pathophysiology and develops a protocol tailored to your unique triggers and barrier status.
Can eczema be cured permanently?
While there is no definitive cure for atopic dermatitis, it can be effectively controlled and many patients experience long periods of remission with proper treatment. Early intervention in childhood may prevent disease progression and reduce severity - this is called the 'window of opportunity.' Approximately 30-50% of children with mild-to-moderate eczema outgrow it by adolescence, though some may reactivate in adulthood due to stress or other triggers. With modern treatments targeting the underlying pathophysiology (barrier dysfunction with ceramides, Th2 inflammation with biologics), many adults achieve near-complete control with minimal side effects. The goal shifts from 'cure' to 'sustained remission with minimal treatment burden and preserved quality of life.'
What triggers eczema flare-ups?
Eczema flare-ups are triggered by a combination of internal and external factors that vary by individual: Environmental allergens (dust mites in bedding/mattresses, pollen, pet dander, mold); Dry skin and low humidity (winter season, air conditioning, heating systems); Hot showers/baths that strip natural oils; Sweating during exercise or in hot weather; Stress (emotional, physical, or environmental); Certain foods (identified through allergy testing or elimination diets); Fragrances and skincare products (soaps, lotions, detergents); Wool and rough/synthetic fabrics; Infections (viral, bacterial, or fungal); Hormonal changes (menstruation, pregnancy). Keeping a detailed symptom diary helps identify your personal trigger pattern so you can develop an effective avoidance strategy.
Is eczema related to diet?
Yes, diet can significantly impact eczema, though food triggers vary significantly between individuals. Approximately 30-40% of people with moderate-to-severe eczema have food allergies or sensitivities that contribute to their condition. Common culprits include dairy, eggs, peanuts, soy, wheat, fish, and shellfish. Food triggers can cause both immediate IgE-mediated reactions (within 2 hours of consumption) and delayed non-IgE-mediated reactions (24-48 hours later). Additionally, inflammatory foods like processed foods, refined sugars, and excessive omega-6 vegetable oils can worsen systemic inflammation that manifests as skin flares. Conversely, anti-inflammatory foods (omega-3 fatty acids, colorful fruits and vegetables) and adequate vitamin D can help control inflammation. An elimination diet under medical supervision or comprehensive food allergy testing can identify your specific triggers.
Why does eczema itch more at night?
Nocturnal pruritus in eczema has several physiological causes: Circadian variation increases skin blood flow and temperature naturally at night, which intensifies itch perception; Cortisol (the body's natural anti-inflammatory hormone) levels naturally drop in the evening and remain low overnight, removing its itch-suppressing effect; Fewer environmental distractions at night allow itch signals to compete more effectively for brain attention; Bedding warmth and sweating during sleep trigger itch receptors; Physical pressure from lying in bed can activate itch pathways; Sleep deprivation itself lowers the itch threshold, creating a vicious cycle. To combat nighttime itching: maintain cool bedroom temperature (65-68°F), use cotton bedding, apply moisturizer before bed, keep nails trimmed, consider antihistamines at night (consult your doctor), and establish a calming bedtime routine.
Does stress cause eczema?
Yes, stress is a significant trigger and contributor to eczema through multiple mechanisms. When you experience stress (emotional, physical, or environmental), your body activates the hypothalamic-pituitary-adrenal (HPA) axis, releasing cortisol and other stress hormones. While short-term cortisol can temporarily suppress inflammation, chronic stress leads to dysregulation that actually worsens immune function and increases Th2 inflammation. Additionally, stress triggers the release of neuropeptides like substance P and CGRP from nerve endings in the skin, which directly activate itch receptors and cause flare-ups. The stress-itch-scratch cycle becomes self-perpetuating: stress causes itch, scratching damages the skin barrier, which causes more inflammation and itch. Managing stress through meditation, cognitive behavioral therapy, yoga, adequate sleep, and relaxation techniques is therefore an essential component of eczema treatment.
Medical References
- 1.1. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-246. doi:10.1111/j.1600-065X.2011.01027.x
- 2.2. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2024;10(1):52. doi:10.1038/s41572-024-00530-0
- 3.3. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2020;156(10):1094-1104. doi:10.1001/jamadermatol.2020.2290
- 4.4. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337-1343. doi:10.1016/j.jaci.2007.12.1162
- 5.5. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. doi:10.1038/jid.2009.133
- 6.6. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1
- 7.7. Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and the microbiome: Translating the hygiene hypothesis to the pathogenesis of atopic dermatitis. J Allergy Clin Immunol Pract. 2020;8(1):84-97. doi:10.1016/j.jaip.2019.09.013
- 8.8. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118(1):152-169. doi:10.1016/j.jaci.2006.03.045
- 9.9. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Part 1: Diagnosis and assessment. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023
- 10.10. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi:10.1111/jdv.14882
- 11.11. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454. doi:10.1038/nature07204
- 12.12. Kim J, Lee J, Lee C, et al. Filaggrin mutations and the atopic march. J Dermatol Sci. 2019;94(1):2-7. doi:10.1016/j.dermsci.2018.12.012
- 13.13. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin. J Allergy Clin Immunol. 2006;117(2):411-417. doi:10.1016/j.jaci.2005.10.033
- 14.14. Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen. J Dermatol Sci. 2012;71(3):131-137. doi:10.1016/j.dermsci.2013.03.001
- 15.15. Geha RS. Allergy and the skin. J Allergy Clin Immunol. 2008;122(2):256-258. doi:10.1016/j.jaci.2008.04.030
Ready to Start Your Healing Journey?
Our integrative medicine experts are ready to help you overcome Eczema & Dermatitis.